The Mechanism of Flecainide Action in CPVT Does Not Involve a Direct Effect on RyR2
Open Access
- 10 April 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 116 (8) , 1324-1335
Abstract
Rationale:: Flecainide, a class 1c antiarrhythmic, has emerged as an effective therapy in preventing arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT) refractory to β-adrenergic receptor blockade. It has been proposed that the clinical efficacy of flecainide in CPVT is because of the combined actions of direct blockade of ryanodine receptors (RyR2) and Na + channel inhibition. However, there is presently no direct evidence to support the notion that flecainide blocks RyR2 Ca 2+ flux in the physiologically relevant (luminal-to-cytoplasmic) direction. The mechanism of flecainide action remains controversial. Objective:: To examine, in detail, the effect of flecainide on the human RyR2 channel and to establish whether the direct blockade of physiologically relevant RyR2 ion flow by the drug contributes to its therapeutic efficacy in the clinical management of CPVT. Methods and Results:: Using single-channel analysis, we show that, even at supraphysiological concentrations, flecainide did not inhibit the physiologically relevant, luminal-to-cytosolic flux of cations through the channel. Moreover, flecainide did not alter RyR2 channel gating and had negligible effect on the mechanisms responsible for the sarcoplasmic reticulum charge-compensating counter current. Using permeabilized cardiac myocytes to eliminate any contribution of plasmalemmal Na + channels to the observed actions of the drug at the cellular level, flecainide did not inhibit RyR2-dependent sarcoplasmic reticulum Ca 2+ release. Conclusions:: The principal action of flecainide in CPVT is not via a direct interaction with RyR2. Our data support a model of flecainide action in which Na + -dependent modulation of intracellular Ca 2+ handling attenuates RyR2 dysfunction in CPVT.Keywords
This publication has 47 references indexed in Scilit:
- Flecainide reduces Ca2+ spark and wave frequency via inhibition of the sarcolemmal sodium currentCardiovascular Research, 2013
- A mechanistic description of gating of the human cardiac ryanodine receptor in a regulated minimal environmentJournal of General Physiology, 2012
- Flecainide Therapy Reduces Exercise-Induced Ventricular Arrhythmias in Patients With Catecholaminergic Polymorphic Ventricular TachycardiaJACC, 2011
- Charade of the SR K+-Channel: Two Ion-Channels, TRIC-A and TRIC-B, Masquerade as a Single K+-ChannelBiophysical Journal, 2010
- Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark massJournal of Molecular and Cellular Cardiology, 2010
- Intrinsic versus extrinsic voltage sensitivity of blocker interaction with an ion channel poreJournal of General Physiology, 2010
- The RYR2-Encoded Ryanodine Receptor/Calcium Release Channel in Patients Diagnosed Previously With Either Catecholaminergic Polymorphic Ventricular Tachycardia or Genotype Negative, Exercise-Induced Long QT SyndromeJACC, 2009
- Closed-channel block of BK potassium channels by bbTBA requires partial activationJournal of General Physiology, 2009
- Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humansNature Medicine, 2009
- The open pore conformation of potassium channelsNature, 2002